Abbott split to take effect from new year
This article was originally published in Clinica
Executive Summary
Abbott Laboratories' board has approved the planned split of its research-based pharmaceuticals business into a separate company called AbbVie. Abbott investors will receive one share of the new company's common stock for every share of Abbott stock they own.